Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Medical Genetics · Glycogen Storage Disease Type IX

Subtypes & Biology: Liver vs. Muscle GSD IX

At a Glance

Glycogen Storage Disease Type IX (GSD IX) has four main subtypes depending on which part of the phosphorylase kinase enzyme is mutated. Types IXa, IXb, and IXc primarily affect the liver, while IXd affects the muscles. Type IXc carries the highest risk for permanent liver scarring.

To understand Glycogen Storage Disease Type IX (GSD IX), it helps to think of the liver as a storage warehouse for energy. The energy is stored in the form of glycogen (a complex chain of sugars) [1]. To use that energy, the body needs a specific “key” to unlock the warehouse and break the glycogen down into glucose (sugar) for the bloodstream.

In GSD IX, the “key” is an enzyme complex called phosphorylase kinase (PhK) [2]. When this enzyme is deficient, the warehouse remains locked. The liver becomes overstuffed with glycogen it cannot release, and the rest of the body may struggle to find enough fuel between meals [3][4].

The Four Subunits of the PhK Enzyme

The PhK enzyme is not a single protein; it is a complex machine made of four different parts called subunits: Alpha (α), Beta (β), Gamma (γ), and Delta (δ) [5][6]. Each subunit is controlled by a different gene, and where the genetic mutation is located determines the specific subtype of GSD IX.

  • The Gamma (γ) Subunit (The Worker): This is the catalytic part of the machine—the part that actually does the work of unlocking the glycogen [5].
  • The Alpha, Beta, and Delta Subunits (The Managers): These are regulatory subunits. They don’t do the unlocking themselves, but they tell the Gamma subunit when to start working and when to stop [7][8].

Understanding the Subtypes

Because these subunits are active in different parts of the body (like the liver or the muscles), symptoms can vary significantly depending on which gene is affected.

Subtype Affected Gene Primary Location Typical Severity
GSD IXa PHKA2 Liver Often mild; improves with age [9]
GSD IXb PHKB Liver & Muscle Generally mild to moderate [10]
GSD IXc PHKG2 Liver More severe; higher risk of liver scarring [11]
GSD IXd PHKA1 Muscle Muscle pain and weakness [12]

Liver-Specific vs. Muscle-Specific

Most patients with GSD IX have the liver-specific form (Types IXa, IXb, and IXc). The most common signs are an enlarged liver (hepatomegaly), high levels of fats in the blood (hyperlipidemia), and low blood sugar or high ketones when fasting [4][13].

In contrast, muscle-specific GSD IX (Type IXd) affects the muscles rather than the liver. These patients may experience myalgia (muscle pain) or weakness, especially after exercise, because their muscles cannot access stored glycogen for quick energy [14][15].

Why is GSD IXc Considered More Severe?

Medical teams pay extra attention if a patient has the IXc subtype (caused by the PHKG2 gene). This is because the PHKG2 gene produces the catalytic (worker) subunit of the enzyme [5].

When the “worker” itself is broken, the enzyme often has much lower activity than when one of the “manager” subunits is affected. Research shows that patients with GSD IXc have a higher risk of developing liver fibrosis (scarring) or even cirrhosis (permanent damage) over time [11][16]. Because of this, they usually require more frequent monitoring and a more proactive management plan to protect the liver [3][2].

Genetics and Inheritance

The subtypes also differ in how they are passed down through families:

  • X-Linked (IXa and IXd): Caused by genes on the X chromosome (PHKA2 and PHKA1). This typically means males are more likely to show symptoms, while females may be asymptomatic carriers or have much milder symptoms [17][9].
  • Autosomal Recessive (IXb and IXc): For these types, a child must inherit one changed gene from each parent to have the condition [18]. Both males and females are affected equally.

For more on how these biological changes cause physical signs, read about Symptoms, Diagnostic Testing & Look-Alikes.

Common questions in this guide

What does the phosphorylase kinase (PhK) enzyme do?
The phosphorylase kinase (PhK) enzyme acts as a key that unlocks stored glycogen in the liver and muscles so it can be broken down into glucose. Without enough of this working enzyme, energy remains trapped in the cells, causing symptoms like fatigue and low blood sugar.
What is the difference between liver and muscle GSD IX?
Liver-specific GSD IX affects how the liver stores and releases sugar, causing an enlarged liver and low blood sugar when fasting. Muscle-specific GSD IX prevents muscles from accessing stored energy, leading to muscle pain and weakness, especially after exercise.
Why is the GSD IXc subtype considered more severe?
GSD IXc is caused by a mutation in the PHKG2 gene, which controls the main catalytic working part of the PhK enzyme. This severely reduces the enzyme's overall ability to function, which increases the risk of permanent liver scarring (fibrosis or cirrhosis) over time.
How are the different subtypes of GSD IX inherited?
The inheritance pattern depends on the specific subtype. Types IXa and IXd are X-linked, meaning males are more frequently and severely affected. Types IXb and IXc are autosomal recessive, meaning a child must inherit a changed gene from both parents, affecting males and females equally.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific gene (PHKA2, PHKB, PHKG2, or PHKA1) is responsible for the GSD IX?
  2. 2.Is this subtype considered liver-specific, muscle-specific, or both?
  3. 3.Given that GSD IXc (PHKG2) carries a higher risk of liver scarring, what is the specific plan for monitoring liver stiffness?
  4. 4.How does the 'catalytic' nature of the PHKG2 subunit explain the severity of symptoms?
  5. 5.Are there any muscle-related symptoms we should be looking for, such as exercise-induced pain or weakness?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Glycogen storage diseases: Twenty-seven new variants in a cohort of 125 patients.

    Sperb-Ludwig F, Pinheiro FC, Bettio Soares M, et al.

    Molecular genetics & genomic medicine 2019; (7(11)):e877 doi:10.1002/mgg3.877.

    PMID: 31508908
  2. 2

    Variability of clinical and biochemical phenotype in liver phosphorylase kinase deficiency with variants in the phosphorylase kinase (PHKG2) gene.

    Waheed N, Saeed A, Ijaz S, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(9)):1117-1123 doi:10.1515/jpem-2019-0603.

    PMID: 32697758
  3. 3

    Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2-/- mouse model.

    Gibson RA, Lim JA, Choi SJ, et al.

    Molecular genetics and metabolism 2021; (133(3)):269-276 doi:10.1016/j.ymgme.2021.05.008.

    PMID: 34083142
  4. 4

    Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report.

    Zamanfar D, Hashemi-Soteh SM, Ghazaiean M, Keyhanian E

    Journal of medical case reports 2024; (18(1)):14 doi:10.1186/s13256-023-04295-0.

    PMID: 38212860
  5. 5

    The structure of the large regulatory α subunit of phosphorylase kinase examined by modeling and hydrogen-deuterium exchange.

    Rimmer MA, Nadeau OW, Yang J, et al.

    Protein science : a publication of the Protein Society 2018; (27(2)):472-484 doi:10.1002/pro.3339.

    PMID: 29098725
  6. 6

    A Mouse Model of Glycogen Storage Disease Type IX-Beta: A Role for Phkb in Glycogenolysis.

    Arends CJ, Wilson LH, Estrella A, et al.

    International journal of molecular sciences 2022; (23(17)) doi:10.3390/ijms23179944.

    PMID: 36077341
  7. 7

    Architecture and activation of human muscle phosphorylase kinase.

    Yang X, Zhu M, Lu X, et al.

    Nature communications 2024; (15(1)):2719 doi:10.1038/s41467-024-47049-2.

    PMID: 38548794
  8. 8

    Molecular basis for the regulation of human phosphorylase kinase by phosphorylation and Ca2.

    Ma R, Du B, Shi C, et al.

    Nature communications 2025; (16(1)):3020 doi:10.1038/s41467-025-58363-8.

    PMID: 40148320
  9. 9

    Clinical and genetic characteristics of 17 Chinese patients with glycogen storage disease type IXa.

    Zhang J, Yuan Y, Ma M, et al.

    Gene 2017; (627()):149-156 doi:10.1016/j.gene.2017.06.026.

    PMID: 28627441
  10. 10

    Glycogen Storage Disorder Type IXb: Exploring Clinical Patterns and Genetic Insights Into a Rare Phosphorylase Kinase B (PHKB)-Associated Case.

    Venkata Renuka I, Ramamoorthy S, B V, et al.

    Cureus 2024; (16(7)):e65474 doi:10.7759/cureus.65474.

    PMID: 39188489
  11. 11

    Benign or not benign? Deep phenotyping of liver Glycogen Storage Disease IX.

    Fernandes SA, Cooper GE, Gibson RA, Kishnani PS

    Molecular genetics and metabolism 2020; (131(3)):299-305 doi:10.1016/j.ymgme.2020.10.004.

    PMID: 33317799
  12. 12

    Recurrent rhabdomyolysis as a presenting feature of glycogenosis IX (GSD IX): a case report.

    Seminara A, Newkirk GT, Durand C

    Archivos argentinos de pediatria 2025; (123(5)):e202410578 doi:10.5546/aap.2024-10578.eng.

    PMID: 40168541
  13. 13

    Glycogen storage disease type IX: Long-term follow-up of 52 patients from three European countries.

    Magner M, Šáhó R, Slavíková P, et al.

    Molecular genetics and metabolism reports 2026; (46()):101297 doi:10.1016/j.ymgmr.2026.101297.

    PMID: 41732189
  14. 14

    A rare co-occurrence of phosphorylase kinase deficiency (GSD type IXd) and alpha-glycosidase deficiency (GSD Type II) in a 53-year-old man presenting with an atypical glycogen storage disease phenotype.

    Picillo E, Onore ME, Passamano L, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2024; (43(1)):21-26 doi:10.36185/2532-1900-411.

    PMID: 38586167
  15. 15

    Hypercholesterolemia Successfully Treated With Two Different PCSK9 Inhibitors in a Patient With Glycogen Storage Disease IXd: Phosphorylase Kinase Deficiency.

    Huynh T, Nguyen H, Nguyen M

    Journal of lipid and atherosclerosis 2026; (15(1)):183-192 doi:10.12997/jla.2026.15.1.183.

    PMID: 41660530
  16. 16

    Progressive liver disease and dysregulated glycogen metabolism in murine GSD IX γ2 models human disease.

    Gibson RA, Jeck WR, Koch RL, et al.

    Molecular genetics and metabolism 2024; (143(4)):108597 doi:10.1016/j.ymgme.2024.108597.

    PMID: 39488079
  17. 17

    [Genetic analysis of a child with glycogen storage disease type IXa due to a novel variant in PHKA2 gene].

    Zhao G, Si W, Zhao X, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2022; (39(9)):988-991 doi:10.3760/cma.j.cn511374-20210610-00495.

    PMID: 36082571
  18. 18

    A novel sequence of the PHKG2 mutation associated with the first case of glycogen storage diseases type IXc in Syria: a case report and review of literature.

    Harh S, Shahoud S, Daher S, Alasmar D

    Journal of medical case reports 2025; (19(1)):317 doi:10.1186/s13256-025-05383-z.

    PMID: 40615918

This page provides educational information about GSD IX subtypes, genetics, and biology. It does not replace professional medical advice from your geneticist, hepatologist, or metabolic specialist.

Get notified when new evidence is published on Glycogen storage disease due to phosphorylase kinase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.